Nadim Ahmed

Nadim Ahmed (chief executive) discloses dealings in 3 companies, chiefly Cullinan Therapeutics, Inc., Bristol Myers Squibb Co and Celgene Corp /DE/. We count 37 filings; the first trade dates from 16 December 2018 and the latest from 24 February 2026.

The open-market side counts 1 purchase for €94k alongside 10 sales for €701k. Netting one side against the other leaves €607k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 16 share grants and 8 option exercises. Since January 2026: no purchases and 2 sales on the market.

The record was last updated on 25 February 2026 with an open-market sale (€166k) in Cullinan Therapeutics, Inc. The clock since the last published purchase (7 June 2022) now reads 1,597 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.